Claims for Patent: 9,844,601

Summary for Patent: 9,844,601

Title:	Multivalent meningococcal polysaccharide-protein conjugate vaccine
Abstract:	The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.
Inventor(s):	Ryall; Robert P. (Stroudsburg, PA)
Assignee:	Sanofi Pasteur Inc. (Swiftwater, PA)
Application Number:	14/855,994
Patent Claims:	1. A method of manufacturing an immunological composition capable of eliciting in children less than two years of age, a primary serum IgG response and a serum bactericidal antibody response to each of Neisseria meningitidis serogroups A, C, W-135 and Y capsular polysaccharides and capable of eliciting a booster anamnestic IgG response to each of the N. meningitidis serogroups A, C, W-135 and Y capsular polysaccharides, the method comprising the steps of: (a) purifying capsular polysaccharides from each of the N. meningitidis serogroups A, C, W-135 and Y; (b) conjugating each of the purified capsular polysaccharides of step (a) to a purified carrier protein in a separate reaction, wherein four distinct and separately made carrier protein-capsular polysaccharide conjugates are made: (c) mixing the four distinct and separately made carrier protein-capsular polysaccharide conjugates of step (b); (d) purifying the admixture of the four distinct and separately made carrier protein-capsular polysaccharide conjugates, wherein the carrier protein is selected from the group consisting of diphtheria toxoid, CRM197 and tetanus toxoid, and further wherein, the serum bactericidal antibody response in children less than two years of age is higher than that elicited by the licensed, unconjugated, tetravalent A, C, W-135 and Y meningococcal capsular polysaccharide vaccine. 2. The method of claim 1, further comprising the step of partially depolymerizing each of the purified N. meningitidis serogroups A, C, W-135 and Y capsular polysaccharides of step (a) using oxidative conditions. 3. The method of claim 2, further comprising the step of activating the depolymerized capsular polysaccharides in a separate reaction. 4. The method of claim 3, wherein said activation step is carried out using adipic acid dihydrazide. 5. A method of manufacturing a conjugate vaccine capable of eliciting in children less than two years of age, a primary serum IgG response and a serum bactericidal antibody response to each of Neisseria meningitidis serogroups A, C, W-135 and Y capsular polysaccharides and capable of eliciting a booster anamnestic IgG response to each of the N. meningitidis serogroups A, C, W-135 and Y capsular polysaccharides, the method comprising the steps of: (a) purifying capsular polysaccharides from each of the N. meningitidis serogroups A, C, W-135 and Y; (b) conjugating each of the purified capsular polysaccharides of step (a) to a purified carrier protein in a separate reaction, wherein four distinct and separately made carrier protein-capsular polysaccharide conjugates are made: (c) mixing the four distinct and separately made carrier protein-capsular polysaccharide conjugates of step (b); (d) purifying the admixture of the four distinct and separately made carrier protein-capsular polysaccharide conjugates, wherein the carrier protein is selected from the group consisting of diphtheria toxoid, CRM197 and tetanus toxoid, and further wherein, the serum bactericidal antibody response in children less than two years of age is higher than that elicited by the licensed, unconjugated, tetravalent A, C, W-135 and Y meningococcal capsular polysaccharide vaccine. 6. The method of claim 5, further comprising the step of partially depolymerizing each of the purified N. meningitidis serogroups A, C, W-135 and Y capsular polysaccharides of step (a) using oxidative conditions. 7. The method of claim 6, further comprising the step of activating the depolymerized capsular polysaccharides in a separate reaction. 8. The method of claim 7, wherein said activation step is carried out using adipic acid dihydrazide. 9. The method of claim 5, wherein the admixture is formulated at 4 .mu.g of each of the four conjugated capsular polysaccharides of N. meningitidis serogroups A, C, W-135 and Y per dose. 10. The method of claim 5, wherein the conjugate vaccine further comprises an adjuvant. 11. The method of claim 10, wherein the adjuvant is an aluminum adjuvant. 12. The method of claim 11, wherein the aluminum adjuvant is aluminum hydroxide. 13. The method of claim 11, wherein the aluminum adjuvant is aluminum phosphate. 14. The method of claim 5, wherein the carrier protein is diphtheria toxoid. 15. The method of claim 5, wherein the carrier protein is CRM197. 16. The method of claim 6, wherein the carrier protein is tetanus toxoid. 17. The method of claim 5, further comprising an auxiliary substance selected from the group consisting of a wetting agent, emulsifying agent, a pH buffering agent, a gelling additive, a viscosity enhancing additive, a preservative, a flavoring agent and a coloring agent. 18. The method of claim 17, wherein said auxiliary substance is a preservative. 19. The method of claim 18, wherein said preservative is selected from the group consisting of parabens, thimerosal, chlorobutanol, benzalkonium chloride and benzyl alcohol. 20. The method of claim 19, wherein said preservative is benzyl alcohol. 21. The method of claim 5, wherein said conjugate vaccine further comprises a suitable carrier, diluent or excipient. 22. The method of claim 21, wherein said suitable carrier, diluent or excipient is selected from the group consisting off sterile water, physiological saline, glucose, sodium tartrate, propylene glycol, sodium chloride, xanthan gum, carboxymethylcellulose, hydroxypropylcellulose, carbomer, and sodium phosphate buffered physiological saline solution. 23. The method of claim 22, wherein said suitable carrier, diluent or excipient is sodium phosphate buffered physiological saline solution.

Details for Patent 9,844,601

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2021-01-23